Early-onset sepsis remains a potentially fatal condition among newborns, particularly preterm infants. According to a study published in JAMA Pediatrics, ongoing surveillance is required to optimize prevention and treatment strategies.
The study included data from 18 centers of the Eunice Kennedy Shriver National Institute of Child Health and Human Development Neonatal Research Network from April 2015 through March 2017. The researchers identified cases of early-onset sepsis – defined as a positive blood or cerebrospinal fluid culture within the first 72 hours of life – from a cohort of more than 200,000 infants, including infants in the Nationwide Children’s Hospital Neonatal Intensive Care Unit (NICU) at The Ohio State University Wexner Medical Center.
The researchers found 235 cases of early-onset sepsis in their cohort, for a rate of 1.08 cases per 1,000 live births. The most frequent pathogens were Escherichia coli (37%) and group B Streptococcus (30%), with E. coli disease primarily occurring among preterm infants and group B streptococcal infection occurring primarily among term neonates. Importantly, 53% of group B streptococcal infections occurred in newborns whose mothers had negative group B streptococcal screening test results.
Neonatal empirical antibiotic treatment most frequently included ampicillin and gentamicin. While the study found that these antimicrobial agents remained effective in most cases, the researchers say that ongoing surveillance should monitor antibiotic susceptibilities of early-onset sepsis pathogens.
“There has not been any resistance of group B Streptococcus to penicillin or ampicillin, which is reassuring,” says Pablo Sánchez, MD, a pediatric infectious diseases specialist and neonatologist who serves as the director of Clinical and Translational Research in Neonatology at Nationwide Children’s Hospital and an author of the study. “However, of 77 E. coli isolates tested for susceptibility to ampicillin and gentamicin, six were found to be resistant to both antibiotics.”
Overall, Dr. Sánchez says continued surveillance is necessary to identify changes in pathogen distribution and antibiotic susceptibilities in this population. To prevent more cases of early-onset sepsis, additional innovative prevention strategies are needed.
“I think this study highlights the fact that we’ve made a lot of progress against group B streptococcal infections, although they remain a problem,” says Dr. Sánchez. “And we still have a lot of work to do to prevent E. coli infections.”